Compare NVCR & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVCR | GSBD |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2015 | 2013 |
| Metric | NVCR | GSBD |
|---|---|---|
| Price | $18.38 | $8.98 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 6 | 2 |
| Target Price | ★ $28.08 | $9.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 13.49% |
| EPS Growth | 21.79 | ★ 87.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $655,353,000.00 | N/A |
| Revenue This Year | $7.72 | N/A |
| Revenue Next Year | $6.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.28 | N/A |
| 52 Week Low | $9.82 | $8.66 |
| 52 Week High | $20.05 | $12.03 |
| Indicator | NVCR | GSBD |
|---|---|---|
| Relative Strength Index (RSI) | 75.89 | 36.05 |
| Support Level | $12.66 | $8.89 |
| Resistance Level | N/A | $9.53 |
| Average True Range (ATR) | 0.99 | 0.24 |
| MACD | 0.48 | -0.11 |
| Stochastic Oscillator | 93.91 | 4.21 |
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.